Search company, investor...

MicroCHIPS Biotech

Founded Year



Acquired | Acquired

Total Raised




About MicroCHIPS Biotech

Microchips Biotech develops implanted medical devices. The Company offers glucose monitors, wireless drug delivery devices, and pace makers. MicroCHIPS serves customers in the United States. On November 20, 2019, Microchips Biotech was acquired by Dare Bioscience at a valuation between $55-101.5M.

Headquarters Location

128 Spring Street Suite 310

Lexington, Massachusetts, 02421,

United States


Missing: MicroCHIPS Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MicroCHIPS Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing MicroCHIPS Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MicroCHIPS Biotech is included in 5 Expert Collections, including Medical Devices.


Medical Devices

8,560 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,530 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,898 items


Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,901 items

MicroCHIPS Biotech Patents

MicroCHIPS Biotech has filed 1 patent.

The 3 most popular patent topics include:

  • Biomaterials
  • Caudovirales
  • Dosage forms
patents chart

Application Date

Grant Date


Related Topics




Microtechnology, Semiconductor device fabrication, Implants (medicine), Nanotechnology, Biomaterials


Application Date


Grant Date



Related Topics

Microtechnology, Semiconductor device fabrication, Implants (medicine), Nanotechnology, Biomaterials



Latest MicroCHIPS Biotech News

Implantable Drug Delivery Devices Global Market Report 2021: COVID 19 Growth And Change to 2030

May 10, 2021

2021: COVID 19 Growth And Change to 2030" - , and Psivida. The global implantable drug delivery devices market is expected to grow from $18.821 billion in 2020 to $20.137 billion in 2021 at a compound annual growth rate (CAGR) of 7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $29.846 billion in 2025 at a CAGR of 10%. The implantable drug delivery devices market consists of sales of implantable drug delivery devices and related services by companies that manufacture them. Implantable drug delivery devices are drug delivery systems implanted by surgery to allow site-specific drug administration at the tissue or organ where the drug is most needed. Companies and researchers are focusing on developing 3D implantable drug delivery devices. 3D printed titanium transcutaneous ports are implanted behind the patient’s ear, allowing healthcare professionals to access the catheters. For instance, in February 2020, Renishaw and Herantis Pharma announced the award-winning device, which received positive results in phase 2 trials, that consists of up to four catheters implanted in the relevant brain areas. Researchers at King Abdullah University of Science and Technology have introduced a miniaturized drug delivery system suitable for in-vivo biomedical applications. The system consists of an electrolytic pump, which operates a micro bellows membrane as an actuator for delivery through microneedles. A two-photon 3D printing technique was used to make a reservoir equipped with a microneedle. The implantable drug delivery device market covered in this report is segmented by product into contraceptive implants; spinal implants; brachytherapy seeds; drug-eluting stents; bio-absorbable stents; intraocular stents; infusion pumps; others. It is also segmented by technology into diffusion; osmotic; magnetic; others, and by application into contraception; ophthalmology; cardiovascular; diabetes; oncology; autoimmune diseases; others. The rising number of product recalls and lawsuits associated with the implantable drug delivery devices is expected to hinder the market.In the past few years, there had been an increase in product recalls and lawsuits connected with these devices. For instance, in December 2019, around 7,000 Medtronic SynchroMed II implantable drug infusion pumps were recalled due to the presence of foreign bodies in them.Nexplanon, a small rod contraceptive implant inserted into the skin of the upper arm to prevent pregnancy for up to three years, is facing a lawsuit, and lawyers and attorneys at National Injury Help have been investigating all such cases against those injured by Nexplanon. Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market. In November 2019, Dare Bioscience, a USA-based biopharmaceutical company with a special focus on women’s health, has acquired Microchips Biotech for an amount of $102 million.Through this acquisition, Microchips has become the wholly subsidiary of Dare Bioscience. Microchips Biotech is a USA-based company developing innovative drug implants. The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases and other chronic diseases is expected to drive the implantable drug delivery devices market.According to the International Diabetes Federation (IDF), the global prevalence of diabetic retinopathy was around 27% between 2015 and 2019. Implantable drug delivery devices are used for site-specific drug administration where the drug is most needed, such as Gliadel® wafer as an implant used in the treatment of brain tumors, Lupron® depot for the treatment of prostate cancer. Hence, due to the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market.

MicroCHIPS Biotech Frequently Asked Questions (FAQ)

  • When was MicroCHIPS Biotech founded?

    MicroCHIPS Biotech was founded in 1999.

  • Where is MicroCHIPS Biotech's headquarters?

    MicroCHIPS Biotech's headquarters is located at 128 Spring Street, Lexington.

  • What is MicroCHIPS Biotech's latest funding round?

    MicroCHIPS Biotech's latest funding round is Acquired.

  • How much did MicroCHIPS Biotech raise?

    MicroCHIPS Biotech raised a total of $94.94M.

  • Who are the investors of MicroCHIPS Biotech?

    Investors of MicroCHIPS Biotech include Dare Bioscience, Keratin Biosciences, Flybridge Capital Partners, Polaris Partners, Medtronic and 11 more.

  • Who are MicroCHIPS Biotech's competitors?

    Competitors of MicroCHIPS Biotech include Aura Biosciences, Erydel, PolyPid, Sol-Gel, Veloxis Pharmaceuticals and 12 more.

Compare MicroCHIPS Biotech to Competitors


CapsuTech is a product driven company focused on research and development of semi-natural, peptide-based, polymers for drug targeting and encapsulation of various chemical and biological entities. Such entities might be drugs, cosmetics, vitamins, food additives, proteins, virions and even cells.nVarious combinations of CapsuTech's modified amino-acid building-blocks provide high-diversity population of polymers and thus enable to formulate almost all molecules and to meet wide spectrum of needs. Such needs include targeting, site-specific release, controlled release. Other characteristics include protection from pH, enzyme proteolysis, oxidation, light and other damaging factors.

Westfield Life Sciences Fund

Launched in July of 2000, the Westfield Life Sciences Fund invests in healthcare companies across the capitalization spectrum including medical devices, drugs, drug delivery, biotechnology, and healthcare services. Portfolio manager Will Muggia employs a fundamental, bottom up research driven process that focuses on preservation of capital and long-term outperformance. Westfield's industry network developed by Mr. Muggia and his analytical team is critical to new idea generation.

Nano Discovery

Nano Discovery aims to provide customer-designed synthesis and development of a range of nanomaterials including nanoparticles, quantum dots, polymers, conjugated conducting polymers, nanofibers, nanotubes, nanoporous particles, colloidal particles (liposomes and vesicles), monolayer and multilayer thin films, and nanocomposite materials. Applications of the materials include biomolecular imaging, bioassay, drug delivery, cancer therapy, electronic materials, coatings and packaging for electronic devices, coatings for corrosion protection, conformable batteries, supercapcitors, and photovoltaic cells. The company also have developed or licensed some signature nanomaterial products which can be made-to-order for the company's customers.

Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Next Breath

Next Breath, LLC is a contract pharmaceutical research and development organization dedicated to pre-clinical identification and evaluation of commercially viable respiratory and nasal drug delivery platforms. NB's business will discover and exploit optimal drug and delivery device combinations that will increase the company's partners' probability of success when their products advance into human clinical trials and the marketplace. Next Breath seeks to meet the pharmaceutical industry's outsourcing needs and to provide intellectual expertise to biotechnology companies that are developing inhalation products.


EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.